Replimune Group Files 8-K
Ticker: REPL · Form: 8-K · Filed: 2025-10-20T00:00:00.000Z
Sentiment: neutral
Topics: corporate-update, filing
TL;DR
Replimune filed an 8-K on 10/20/25, updating corporate info. All good.
AI Summary
Replimune Group, Inc. filed an 8-K on October 20, 2025, reporting on other events and financial statements. The filing details the company's principal executive offices located at 500 Unicorn Park Drive, Suite 303, Woburn, MA 01801, and its principal executive office phone number is (781) 222-9600. The company is incorporated in Delaware and its fiscal year ends on March 31.
Why It Matters
This 8-K filing provides updated corporate information and signals ongoing regulatory and financial activities for Replimune Group, Inc.
Risk Assessment
Risk Level: low — This filing is a routine corporate update and does not contain information that suggests immediate financial risk.
Key Players & Entities
- Replimune Group, Inc. (company) — Registrant
- October 20, 2025 (date) — Date of earliest event reported
- 500 Unicorn Park Drive Suite 303 Woburn , MA 01801 (address) — Address of principal executive offices
- ( 781 ) 222-9600 (phone_number) — Registrant's telephone number
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is REPLIMUNE GROUP, INC.
On what date was the earliest event reported in this 8-K filing?
The date of the earliest event reported is October 20, 2025.
What is the principal executive office address of Replimune Group, Inc.?
The address of the principal executive offices is 500 Unicorn Park Drive Suite 303 Woburn, MA 01801.
What is the telephone number of Replimune Group, Inc.?
The registrant's telephone number, including area code, is (781) 222-9600.
In which jurisdiction is Replimune Group, Inc. incorporated?
Replimune Group, Inc. is incorporated in Delaware.
Filing Stats: 473 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-10-20 07:20:45
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share REPL The Nasdaq Stock Mar
Filing Documents
- tm2529069d1_8k.htm (8-K) — 26KB
- tm2529069d1_ex99-1.htm (EX-99.1) — 9KB
- 0001104659-25-100605.txt ( ) — 200KB
- repl-20251020.xsd (EX-101.SCH) — 3KB
- repl-20251020_lab.xml (EX-101.LAB) — 33KB
- repl-20251020_pre.xml (EX-101.PRE) — 22KB
- tm2529069d1_8k_htm.xml (XML) — 4KB
01 Other
Item 8.01 Other Events . On October 20, 2025, Replimune Group, Inc. (the "Company") issued a news release announcing that the U.S. Food and Drug Administration (the "FDA") accepted the Company's resubmission of the Biologics License Application for RP1 in combination with nivolumab for patients with advanced melanoma. The PDUFA date set by the FDA is April 10, 2026 based on a Class II resubmission timeline. A copy of the news release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein. The Company undertakes no obligation to update, supplement or amend the materials attached hereto.
01 Financial
Item 9.01 Financial Statements and Exhibits . Exhibit No. Description 99.1 News Release dated October 20, 2025 104 Cover page interactive data file (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIMUNE GROUP, INC. Date: October 20, 2025 By: /s/ Sushil Patel Sushil Patel Chief Executive Officer